Alzheimer's & dementia : the journal of the Alzheimer's Association

Using a blood marker and frontotemporal brain shrinkage to better distinguish behavioral variant frontotemporal dementia from psychiatric disorders

Updated

Abstract

Both atrophy and (NfL) showed significant predictive ability for differentiating behavioral variant frontotemporal dementia (bvFTD) from primary psychiatric disorders (PPDs), with AUC values of 0.87 and 0.89, respectively.

  • Atrophy and NfL levels are elevated in bvFTD compared to PPDs.
  • Combining atrophy and NfL improves predictive accuracy, reaching an AUC of 0.93.
  • Misclassification tends to occur in patients with low atrophy and borderline NfL levels.
  • Additional markers may be necessary to enhance differentiation in ambiguous cases.
  • The findings suggest a potential approach for screening neurodegeneration in complex clinical scenarios.

Simplified

Key numbers

0.93
AUC for combined model
Area under the curve for the combined and atrophy model.
0.89
AUC for -only model
Area under the curve for the -only model.
0.87
AUC for atrophy-only model
Area under the curve for the atrophy-only model.

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Dr. Bill Seeley serves as a paid consultant on the scientific advisory board for Lyterian Therapeutics. Dr. Bruce Miller serves on the scientific advisory board of the Bluefield Project to Cure FTD; the John Douglas French Alzheimer's Foundation; Fundación Centro de Investigación Enfermedades Neurológicas, Madrid, Spain; Genworth, Inc.; the Kissick Family Foundation; the Larry L. Hillblom Foundation; and the Tau Consortium of the Rainwater Charitable Foundation; serves as a scientific advisor for the Arizona Alzheimer's Consortium, Massachusetts General Hospital ADRC, and the Stanford University ADRC; receives royalties from Cambridge University Press, Elsevier, Inc., Guilford Publications, Inc., Johns Hopkins Press, Oxford University Press, and the Taylor & Francis Group; serves as editor for Neurocase and section editor for Frontiers in Neurology ; and receives grants P0544014 for the UCSF FTD Core from the Bluefield Project to Cure FTD and R01AG057234 from the NIH/NIA for the US‐South American Initiative for Genetic‐Neural‐Behavioral Interactions in Human Neurodegenerative Diseases. Dr. Miller receives no support, financial or otherwise, from an ineligible company such as those whose primary business is producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Dr. Andrew Krystal: Research Grants: Alkermes; Janssen Pharmaceuticals, Axsome Pharmaceutics, Attune, Eisai, Harmony, Neumora; Neurocrine Biosciences, Reveal Biosensors, The Ray and Dagmar Dolby Family Fund, Weill Institute for Neurosciences, and the National Institutes of Health. Consulting: Axsome Therapeutics, Abbvie, Big Health, Eisai, Evecxia, Harmony Biosciences, Idorsia, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Neurocrine Biosciences, Neumora, Neurawell, Otsuka Pharmaceuticals, Sage, Takeda. Stock Options: Neurawell, Big Health. All remaining authors declare no conflicts of interest. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Author disclosures are available in the Supporting Information.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free